A brand new weekly injectable drug may rework the lives of greater than eight million folks dwelling with Parkinson’s illness, probably changing the necessity for a number of each day tablets.
Scientists from the College of South Australia (UniSA) have developed a long-acting injectable formulation that delivers a gradual dose of levodopa and carbidopa – two key medicines for Parkinson’s – over a whole week.
Their findings have been reported within the journal Drug Supply and Translational Analysis.
The biodegradable formulation is injected beneath the pores and skin or into muscle tissue, the place it steadily releases the medicine over seven days.
Parkinson’s illness is the second commonest neurological dysfunction, affecting greater than 8.5 million folks worldwide. At the moment there isn’t a treatment and the signs – tremors, rigidity and gradual motion – are managed with oral medicines that should be taken a number of instances a day.
The frequent dosing is a burden, particularly for aged sufferers or these with swallowing difficulties, resulting in inconsistent medicine ranges, extra unintended effects, and decreased effectiveness.
Lead researcher Professor Sanjay Garg, from UniSA’s Centre for Pharmaceutical Innovation, says the newly developed injectable may considerably enhance therapy outcomes and affected person adherence.
Our purpose was to create a formulation that simplifies therapy, improves affected person compliance, and maintains constant therapeutic ranges of medicine. This weekly injection may very well be a game-changer for Parkinson’s care.
Levodopa is the gold-standard remedy for Parkinson’s, however its quick life span means it should be taken a number of instances a day.”
Professor Sanjay Garg, from UniSA’s Centre for Pharmaceutical Innovation
UniSA PhD scholar Deepa Nakmode says the in-situ implant is designed to launch each levodopa and carbidopa steadily over one week, sustaining constant plasma ranges and lowering the dangers related to fluctuating drug concentrations.
The injectable gel combines an FDA-approved biodegradable polymer PLGA with Eudragit L-100, a pH-sensitive polymer, to realize a managed and sustained drug launch.
In depth lab exams confirmed the system’s effectiveness and security:
- Greater than 90% of the levodopa dose and greater than 81% of the carbidopa dose was launched over seven days.
- The implant degraded by over 80% inside every week and confirmed no vital toxicity in cell viability exams.
- The formulation could be simply administered by way of a fantastic 22-gauge needle, minimising discomfort and eliminating the necessity for surgical implant.
“The implications of this analysis are profound,” Prof. Garg says. “By lowering the frequency of dosing from a number of instances a day to a weekly injection is a serious step ahead in Parkinson’s remedy. We’re not simply enhancing how the drug is delivered; we’re enhancing sufferers’ lives.”
Prof. Garg says the know-how may be tailored for different power situations corresponding to most cancers, diabetes, neurodegenerative issues, ache administration, and power infections that require long-term drug supply.
The system could be tuned to launch medication over a interval starting from a number of days to a number of weeks relying on therapeutic wants.
UniSA scientists hope to begin medical trials within the close to future and are exploring commercialisation alternatives.
Supply:
Journal reference:
Nakmode, D. D., et al. (2025). Improvement of an in-situ forming implant system for levodopa and carbidopa for the therapy of parkinson’s illness. Drug Supply and Translational Analysis. doi.org/10.1007/s13346-025-01892-y.